TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Kettlebell Training Measured Across Power and Performance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion~* Male and Female Cadets~* Age 18-27~* Emancipated minor at age 17~* Remedial physical training participant~Exclusion~* Self-reported pregnancy~* Participants who are not fluent in English~* History of a musculoskeletal injury in the last month~* Any history of a spondylolisthesis~* History of an orthopedic surgery in the last six months~* Condition that results in surgery during the study,~* Missing \>1 exercise session per week

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 27 Years
- Healthy Volunteers: t

Study Arms:
- Kettlebell Training (Type: EXPERIMENTAL): Army Physical Readiness Training (PRT) with kettlebell training in place of strength training circuits
- Army Physical Readiness Training (Type: ACTIVE_COMPARATOR): Army Physical Readiness Training (PRT) per Army Field Manual 7-22

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Androgen Blockade Therapy on Thymus Function in Older Patients Who Have Undergone Radical Prostatectomy for Localized Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~* Underwent prior radical prostatectomy as local definitive therapy for prostate cancer~* Meets criteria for 1 of the following strata:~  * Has received ≥ 9 months of androgen blockade therapy (either single-agent luteinizing hormone-releasing hormone or combined androgen blockade) for serologic progression after surgery~    * Serologic progression defined as a rising prostate-specific antigen, which has risen serially on two determinations (from baseline) ≥ 1 week apart, and no objective evidence of metastatic disease~   * Prior radiotherapy for serologic progression allowed~ * Did not receive any form of androgen blockade therapy within the past 9 months~* No metastatic disease by abdominal/pelvic CT scan and whole-body scan~PATIENT CHARACTERISTICS:~* Able to tolerate CT scanning in the supine position~* No prior medical condition known to have effects on the thymus, including myasthenia gravis, lymphoma, hyperthyroidism, or cachexia~* No autoimmune disorders~* No acute illness, including active infection requiring antibiotics~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior systemic chemotherapy~* No prior immunological therapy~* No prior single-agent antiandrogen (e.g., high-dose bicalutamide)~* No prior or concurrent 5-alpha reductase inhibitors (e.g., finasteride), PC-SPES, or estrogen-containing nutraceuticals~* No concurrent systemic steroid therapy (topical steroids allowed)

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Continuous Glucose Monitoring in Neonates With Hypoglycemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Age 0-60 days old~* Late-preterm and term infants (babies born more than 33 weeks and 6 days after the start of the pregnancy)~* History of low blood sugars (hypoglycemia): two episodes of hypoglycemia more than 1 hour apart (low blood sugar will be defined by age: for those less than 48 hours old a low blood sugar is considered less than 50mg/dL and for those older than 48 hours old less than 70mg/dL)~Exclusion Criteria:~* Infants with skin disease such that placement of a glucose sensor under the skin would be difficult to secure~* Infants expected to remain in NICU less than 24 hours~* Infants on a hypothermic protocol~* Infants enrolled in a competing clinical trial~* Family/team have decided to limit or redirect from aggressive NICU technological support~* infants who are wards of the state

- Gender: ALL
- Minimum Age: None
- Maximum Age: 60 Days
- Healthy Volunteers: f

Study Arms:
- CGM Protocol (Type: EXPERIMENTAL): Subjects will receive continuous glucose monitoring and caregivers will be able to view continuous glucose measurements.
- Standard of Care (Type: PLACEBO_COMPARATOR): Subjects will receive continuous glucose monitoring but caregivers will not be able to view continuous glucose measurements.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pulsed 1064nm Nd:YAG in the Treatment of Verruca Vulgaris Versus Conventional Therapy With Liquid Nitrogen Cryotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult males or females, ages 18 - 75~2. Fitzpatrick skin types 1-6~3. Patient is able to read and understand English and will give written informed consent to participate.~4. Patient elects to undergo laser therapy or conventional therapy with liquid nitrogen for the treatment of verruca vulgaris.~5. Clinical evidence of at least one verruca vulgaris, but no more than ten that have not received treatment for at least one month prior to their study start date.~6. Warts to be treated will be located only on the hands or the feet.~Exclusion Criteria:~1. Less than 18 years of age or greater than 75 years of age.~2. Non-English speaking people, who cannot read, understand and sign the consent.~3. Pregnant females.~4. Any form of prior treatment to the area within the last 1 month.~5. Immunosuppressed patients including patients with internal malignancy, on immunosuppressive drugs (including oral steroids), HIV positive or history of connective tissue disease (ie. SLE, DM, Scleroderma).~6. Patients undergoing light therapy including NBUVB, PUVA, high UVB will be excluded from the study until their treatment is complete.~7. Allergy to any components of the topical lidocaine (LMX, 4% lidocaine).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Liquid Nitrogen Cryotherapy (Type: ACTIVE_COMPARATOR): Every two weeks for a total of 5 treatments or until the patient clears, patients in the cryotherapy arm will be treated with 5-7 seconds of freeze time maintaining a 1mm freeze halo around the wart.
- Pulsed 1064nm Nd:YAG (Type: EXPERIMENTAL): Every 2 weeks for a total of five treatments or until the wart clears, patients in the laser arm will be treated with the Nd:YAG. The settings will be 180J, 20ms pulse width and 5mm spot size. For warts 3mm or less, a 3mm spot size will be used, 180J and 15ms. If the patient reports no response after treatment, including crusting or blistering, the energy will be increased by 10 J until 200J has been reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Extracorporeal Membrane Oxygenation (ECMO): Blood Cells

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
ECMO group:~Inclusion Criteria:~* Greater than or equal to 18 years of age~* Subject presents to the CTICU at Butterworth Campus, Spectrum Health and is critically ill in the ICU needing ECMO therapy.~Exclusion Criteria:~* Subject is less than 18 years of age~* Known prisoner~Control Subjects:~Inclusion Criteria~* Greater than 18 years of age~* Without any known cardiovascular, lung, or autoimmune disease.~Exclusion Criteria:~* Less than or equal to 18 years of age~* Known cardiovascular, lung, or autoimmune disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ECMO (Type: None): No intervention. Blood specimen collection.
- Control (Type: None): No intervention. Blood specimen collection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion:~* Patients with a haploidentical related HLA donor and hemoglobin SS, hemoglobin SC, or hemoglobin Sb0/+ thalassemia and at least one of the following conditions:~  1. previous central nervous system vaso-occlusive episode with or without residual neurologic findings;~ 2. frequent painful vaso-occlusive episodes which significantly interfere with normal life activities and which necessitate chronic transfusion therapy;~ 3. recurrent SCD chest syndrome events, which necessitate chronic transfusion therapy;~ 4. severe anemia, which prevents acceptable quality of life and necessitates chronic transfusion therapy.~* Patients with a haploidentical related HLA donor and homozygous b0/+ thalassemia or severe variants of b0/+ thalassemia and require chronic transfusion therapy.~* Women of childbearing potential must have a negative pregnancy test.~* Between the ages of birth and 65 years.~Exclusion:~* HLA identical or 5/6 HLA matched sibling donor~* Biopsy proven chronic active hepatitis or portal fibrosis.~* SCD chronic lung disease \> stage 3 Severe renal dysfunction defined as creatinine clearance \<40 ml/min/1.73 M2.~* Severe cardiac dysfunction defined as shortening fraction \<25%.~* HIV infection.~* Unspecified chronic toxicity serious enough to detrimentally affect the patient's capacity to tolerate Stem Cell Transplant.~* Patient or guardian(s) unable to understand the nature and risks inherent in the stem cell transplant process.~* Pregnant or lactating females and those unwilling to use acceptable contraception.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A 6-Month Extension Study of OTO-104 in Meniere's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria includes, but is not limited to:~* Subject has completed the Phase 2 OTO-104 1-Year Safety Study (104-201403) or Phase 3 (104-201508) clinical study.~* Subject has a diagnosis of definite unilateral Meniere's disease by 1995 AAO-HNS criteria~Exclusion Criteria includes, but is not limited to:~* Subject is pregnant or lactating.~* Subject has a history of immunodeficiency disease.~* Subject has experienced an adverse reaction to intratympanic injection of steroids.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OTO-104 (Type: EXPERIMENTAL): 12 mg dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Paracetamol With Caffeine to Treat Episodic Tension Type Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of episodic tension-type headache consistent with all of the following:~  1. number of days with the condition is historically greater than or equal to two per month~ 2. onset of condition was greater than or equal to 12 months from Visit 1~ 3. age of onset was \< 50 years~ 4. severity of headaches is historically at least moderate~ 5. duration of headaches is historically greater than or equal to four hours, if untreated~ 6. number of headache episodes was greater than or equal to 4 and less than or equal to 10 during each of the three months immediately prior to Visit 1~ 7. treatment of headache episodes with OTC analgesics has historically provided pain relief in less than or equal to 2 hours~Exclusion Criteria:~* Subject has chronic tension type headache, which is defined as headache on more than 15 days per month for 3 months.~* If a migraine sufferer,subject averages more than one episode per month, is incapable of differentiating between tension-type headaches and migraine headaches, and/or requires regular or prophylactic use of migraine medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: PLACEBO_COMPARATOR): Placebo
- Arm 2 (Type: ACTIVE_COMPARATOR): paracetamol marketed forumulation
- Arm 3 (Type: ACTIVE_COMPARATOR): ibuprofen marketed formulation
- Arm 4 (Type: EXPERIMENTAL): experimental paracetamol + caffeine formulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Automated Anesthesia Guided by the Conox Monitor for Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled surgery for at least one hour~* Consent for participation~* Affiliation to the social security system~Exclusion Criteria:~* Pregnant or breastfeeding women~* Patients for which Conox monitor should not be used~* Allergies to propofol or remifentanil

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Full automation group (Type: EXPERIMENTAL): Full automation control of propofol and remifentanil
- Control group (Type: OTHER): Manual control of of propofol and remifentanil using TCI system

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of GC4419 in Patients With Critical Illness Due to COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects at least 18 years of age.~2. Ability to understand and the willingness to sign a written informed consent.~3. Laboratory-confirmed SARS-CoV-2 infection as determined by a positive PCR test documented prior to randomization~4. Requirement for intensive inpatient hospital care~5. Acute hypoxemic respiratory failure typifying ARDS~6. Adequate liver function~7. Use of effective contraception~Exclusion Criteria:~1. Expected survival for less than 48 hours after randomization~2. Child-Pugh stage C hepatic impairment and/or portal hypertension secondary to cirrhosis~3. Stage IV chronic kidney disease or end-stage kidney disease on maintenance hemodialysis~4. Requirement for extra-corporeal membrane oxygenation (ECMO)~5. Acute Myocardial Infarction (AMI)~6. Active bleeding requiring transfusion~7. Concurrent participation in another clinical trial of experimental treatment for SARSCoV-2~8. Female patients who are pregnant or breastfeeding~9. Requirement for concurrent treatment with nitrates

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active GC4419 (Type: EXPERIMENTAL): Arm A
- Placebo (Type: PLACEBO_COMPARATOR): Arm B

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: PET/CT Evaluation of Treatment Response in Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Subjects must have histologically proven breast cancer~* Subjects are being considered for preoperative chemotherapy~* Subjects must be ≥ 18 years old. Sensor Sub-Study Only~* Palpable subcutaneous or known disease with one surface \<1cm below surface of skin.~* A subset of patients who have a mass located on any surface of the breast that is accessible for Lucerno sensor placement will have additional testing.~Exclusion Criteria~* Children will be excluded from this study.~* Pregnant women and women who are breast feeding will be excluded from this study. (The Vanderbilt University Medical Center radiology PET Procedure Screening Form will be used to identify and exclude subjects who are pregnant or breastfeeding. A urine pregnancy test/or serum beta HCG will also be performed for women of child bearing potential).~* Patients who are acutely ill who are deemed by their treating physician as not suitable candidates for this study.~* Intraluminal lesions will be excluded from the sensor sub-study.~* Non biopsy proven malignancy will be excluded from this study.~* Palpable subcutaneous or known disease with one surface \>1cm below surface of skin will be excluded from the sensor sub-study.~* Draining or exposed malignant tumor will be excluded from the sensor sub-study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- fluorodeoxyglucose PET/CT (FDG-PET/CT) (Type: EXPERIMENTAL): A PET/CT scan prior to the initiation of therapy, and then two additional scans following the initiation of therapy. Each patient will have up to three scans in a 6 month time frame.
- fluorodeoxythymidine PET/CT (FLT-PET/CT) (Type: EXPERIMENTAL): A PET/CT scan prior to the initiation of therapy, and then two additional scans following the initiation of therapy. Each patient will have up to three scans in a 6 month time frame.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lung Cancer Case Registry and Tissue Resource

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Potential participants in the Lung Cancer Case Registry will be all patients diagnosed or evaluated for possible treatment of lung cancer at the CRTC and NMVHCS. Recruiting will primarily be performed through the Multidisciplinary Chest Clinics held weekly at each hospital. These clinics are staffed by the Principal Investigator (PI) and Reza Mehran, MD, a thoracic surgeon at both hospitals and a co-investigator on this submission. Approximately 90% of all lung cancer cases diagnosed at the NMVHCS, and a somewhat smaller proportion of cases treated in the Cancer Center, are seen in these clinics. Additional cases will be identified through review of new patient visits to each hospital with a diagnosis of lung cancer; Drs. Crowell and Mehran also maintain weekly contact with pathology and oncology services at both facilities, which will facilitate case identification at NMVHCS and University Hospital. Finally, patient contact records will be correlated with tumor registry records at both hospitals, which will identify any cases not captured through the above mechanisms. Although these cases may be identified several weeks after initial diagnosis, all attempts will still be made to contact the patient and family for enrollment into the registry. Most Spanish-speaking patients served by the CRTC and the NMVHCS are bilingual, and a language barrier has not been a problem in other similar studies conducted by the PI. However, Spanish-speaking personnel are available to obtain consent and answer any questions if necessary.~Exclusion Criteria:~* Patients will be excluded if they cannot provide written informed consent.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Low-dose Molecular Breast Imaging: Comparison of Breast Cancer Detection Rate at Initial Screening and Two-year Follow-up

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- Past prior screening mammogram within the previous 11-24 months interpreted as heterogeneously dense or extremely dense and negative or benign \[Breast Imaging Reporting and Data System (BI-RADS) Category 1 or 2\]~Exclusion Criteria:~Subjects will be excluded if they:~* Are unable to understand and sign the consent form~* Are pregnant or lactating~* Are physically unable to sit upright and still for 40 minutes~* Have self-reported signs or symptoms that may suggest breast cancer (palpable mass, bloody nipple discharge, axillary mass, etc.)~* Have had needle biopsy within 3 months, or breast surgery or radiation within 1 year prior to the study~* Are currently receiving chemotherapy or tamoxifen, raloxifene, or an aromatase inhibitor for adjuvant therapy or chemoprevention~* Have undergone bilateral mastectomy~* Have had a prior MBI within 20 months of scheduled study MBI.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Molecular Breast Imaging (Type: EXPERIMENTAL): Molecular Breast Imaging (MBI) utilizes small high resolution gamma camera detectors in a dual-detector configuration to image the breast following the administration of a radiopharmaceutical that accumulates preferentially in breast tumors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility